Example: quiz answers
Hyoscine Hydrobromide BP
Data Sheet – New Zealand Hosp 3.0 1 DBL™ HYOSCINE INJECTION BP Hyoscine Hydrobromide BP Description O O HOH H N CH3 O HBr 3H 2O The molecular formula of hyoscine hydrobromide is C
Tags:
Information
Domain:
Source:
Link to this page:
Documents from same domain
ADVANTAN Presentation Uses - Medsafe
www.medsafe.govt.nzADVANTAN® Data Sheet Page 1 of 9 ADVANTAN® Methylprednisolone aceponate 0.1% ointment/cream . Presentation 1 g cream or ointment contains 1 mg (0.1%) methylprednisolone aceponate.
LOXALATE 1. Product Name - Medsafe Home Page
www.medsafe.govt.nzPage 5of 21 at risk, such as the elderly, or patients with cirrhosis, or if used in combination with other medications which may cause hyponatraemia.
DATA SHEET 1 CLEXANE AND CLEXANE FORTE ... - …
www.medsafe.govt.nzNew Zealand Data Sheet June 2017 . clexane-clexane-forte-ccdsv13-dsv18-16jun17 Page 2 . 100 mg injection enoxaparin sodium 100mg (equivalent to …
SEPTANEST Articaine hydrochloride 4% with …
www.medsafe.govt.nzSEPTANEST Articaine hydrochloride 4% with adrenaline 1:100,000 Injection for local and regional dental anaesthesia DESCRIPTION SEPTANEST is a sterile aqueous solution that contains articaine hydrochloride 4% (40 mg/mL) with adrenaline acid tartrate in a 1:100,000 strength.
BOOSTRIX - Medsafe Home Page
www.medsafe.govt.nz1 BOOSTRIX®. Combined diphtheria, tetanus, acellular pertussis (dTpa) vaccine . CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET? This leaflet answers some of the common questions about BOOSTRIX vaccine.
NEW ZEALAND DATA SHEET - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET Cymevene ® DS 170831 2 of 26 Caution: Cymevene must only be administered by IV infusion over 1 hour, preferably via a
Edition Draft - Medsafe
www.medsafe.govt.nzPart 4, Ed Draft Page 2 of 9 Section 1: Good Manufacturing Practice Documentation 1.1. When is GMP Documentation Required? Medsafe requires evidence of Good Manufacturing Practice (GMP) compliance for
Data Sheet 1 PRODUCT NAME 2 QUALITATIVE AND …
www.medsafe.govt.nzNew Zealand Data Sheet 31 July 2017 Lantus – insulin glargine lantus-ccdsv19-dsv11-31jul17 Page 1 Data Sheet 1 PRODUCT NAME Lantus 100 IU/mL solution for injection in 10 …
NEW ZEALAND DATA SHEET MESTINON® - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET MESTINON® MESTINON Page 4 of 8 As the severity of myasthenia gravis often fluctuates considerably, particular care is required to
DATA SHEET PREDNISONE - Medsafe
www.medsafe.govt.nz• Epilepsy and/or seizure disorder • Peptic ulceration • Previous steroid myopathy • Tuberculosis • Patients with myasthenia gravis receiving anticholinesterase therapy since
Related documents
120911 Nal CSL DS clean - Medsafe Home Page
www.medsafe.govt.nzNaloxone 11th Sep 2012 3 Use with caution in patients (including the elderly) with pre-existing cardiovascular disease and in those receiving medications with potential adverse cardiovascular effects, such as hypotension,
Alepam - Medicines
www.medicines.org.auAlepam – Product Information 4 palpitations, panic attacks, vertigo, myoclonus, akinesia, hypersensitivity to light, sound and touch, abnormal body sensations (e.g. feelings of motion, metallic taste), depersonalisation, derealisation, delusional beliefs, hyperreflexia
Review of the role of mannitol in the therapy of …
www.who.int18th Expert Committee on the Selection and Use of Essential Medicines (21 to 25 March 2011) Section 16: Diuretics -- Mannitol review (Children)
Introduction to Neuroscience and its Influence on …
issbd.orgIntroduction to Neuroscience and its Influence on Studying Human Development Karina Weichold University of Jena, Germany E-mail: karina.weichold@uni-jena.de
Morphine Administration - Auckland District Health …
www.adhb.govt.nzStarship Children’s Health Clinical Guideline Note: The electronic version of this guideline is the version currently in use. Any printed version can
APO-DIAZEPAM TABLETS NAME OF THE MEDICINE
www.medicines.org.auProduct Information – Australia APO-Diazepam tablets Page 3 Since the tablets contain lactose, patients with rare hereditary problems of galactose intolerance (the
FDA Recommends Against Prolonged Use of …
www.fda.govFDA Recommends Against Prolonged Use of Magnesium Sulfate to Stop Pre-term Labor Due to Bone Changes in Exposed Babies . Safety Announcement [5-30-2013] The U.S. Food and Drug Administration (FDA) is advising health care